【Event Report】Sponsored Session at the CBI Annual Meeting 2025: GPU × AI-Powered Drug Discovery R&D — Sharing Knowledge and Growing the Tokyo-1 Community

On October 30, Xeureka hosted a sponsored session at the CBI Annual Meeting 2025 titled, “GPU × AI-Powered Drug Discovery R&D — Sharing Knowledge and Growing the Tokyo-1 Community”

A year and a half since the launch of Tokyo-1, the use of GPU × AI has become standard practice across research sites of participating companies, and community activities have continued to evolve and deepen. In this session, our CTO (Hiroki Makiguchi) and the head of Tokyo-1 (Naoki Shiraishi) introduced the latest initiatives from Tokyo-1 as well as cross-organization knowledge cultivated through the community. Representatives from participating companies (Kazuya Nagaoka of Astellas Pharma, Masakuni Kurono of Ono Pharmaceutical, and Shunya Makino of Daiichi Sankyo) shared practical insights on implementing and operationalizing AI in their day-to-day work, key considerations for its effective use, as well as the benefits achieved and lessons learned along the way.

During the panel discussion, moderated by Koji Hirahata of NVIDIA, participants took a deeper dive into the extent of AI integration in real-world operations and the resulting efficiency gains, drawing on hands-on experience from the field.

We are grateful that so many of you joined us again this year, following on last year’s successful meeting.

Xeureka remains committed to contributing significant improvements in the efficiency and success rate of drug discovery research by providing advanced computational drug discovery solutions and the large-scale, high-speed computing environment Tokyo-1.

For more details, please refer to the following link:
Sponsored Session CBI2025